Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112?iglB::fljB.
Ontology highlight
ABSTRACT: Oral vaccination with the defined live attenuated Francisella novicida vaccine strain U112?iglB has been demonstrated to induce protective immunity against pulmonary challenge with the highly human virulent Francisella tularensis strain SCHU S4. However, this vaccination regimen requires a booster dose in mice and Exhibits 50% protective efficacy in the Fischer 344 rat model. To enhance the efficacy of this vaccine strain, we engineered U112?iglB to express the Salmonella typhimurium FljB flagellin D1 domain, a TLR5 agonist. The U112?iglB::fljB strain was highly attenuated for intracellular macrophage replication, and although the FljB protein was expressed within the cytosol, it exhibited TLR5 activation in a TLR5-expressing HEK cell line. Additionally, infection of splenocytes and lymphocytes with U112?iglB::fljB induced significantly greater TNF-? production than infection with U112?iglB. Oral vaccination with U112?iglB::fljB also induced significantly greater protection than U112?iglB against pulmonary SCHU S4 challenge in rats. The enhanced protection was accompanied by higher IgG2a production and serum-mediated reduction of Francisella infectivity. Thus, the U112?iglB::fljB strain may serve as a potential vaccine candidate against pneumonic tularemia.
SUBMITTER: Cunningham AL
PROVIDER: S-EPMC4140432 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA